HM Payson & Co. Buys 1,128 Shares of Edwards Lifesciences Co. (NYSE:EW)

HM Payson & Co. lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 18.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,233 shares of the medical research company’s stock after acquiring an additional 1,128 shares during the period. HM Payson & Co.’s holdings in Edwards Lifesciences were worth $477,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Park Avenue Securities LLC boosted its holdings in Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares during the last quarter. City State Bank lifted its stake in Edwards Lifesciences by 16.5% in the second quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after acquiring an additional 130 shares during the last quarter. Choreo LLC lifted its stake in Edwards Lifesciences by 4.1% in the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after acquiring an additional 153 shares during the last quarter. Stableford Capital II LLC lifted its stake in Edwards Lifesciences by 2.7% in the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after acquiring an additional 159 shares during the last quarter. Finally, Purus Wealth Management LLC raised its position in shares of Edwards Lifesciences by 5.2% in the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 160 shares during the period. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several research analyst reports. Robert W. Baird dropped their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Piper Sandler lowered their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Finally, Citigroup decreased their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a report on Tuesday, October 1st. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Up 0.8 %

NYSE:EW opened at $67.54 on Friday. The firm’s 50 day simple moving average is $67.92 and its 200 day simple moving average is $77.69. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a market cap of $40.69 billion, a PE ratio of 9.75, a P/E/G ratio of 3.86 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the company earned $0.59 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,250 shares of company stock worth $1,099,238. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.